Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA PHARMACEUTICALS LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Robert Hooper
Date of last notice	23/01/2017

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	30/01/2017	
No. of securities held prior to change	33,657,388	
	Ordinary Shares	8,710,573
	Shares allocated pursuant to the employee share plan	33,612
	Shares allocated pursuant to the loan funded long term incentive plan	24,675,526
	Short term incentive plan performance rights	237,677

<sup>+</sup> See chapter 19 for defined terms.

Class	Ordinary	
Number acquired	N/A	
Number disposed	600,000	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$726,708.00	
No. of securities held after change	33,057,388	
	Ordinary Shares 8,110,573	
	Shares allocated pursuant to the employee share plan 33,612	
	Shares allocated pursuant to the loan funded long term incentive plan 24,675,526	
	Short term incentive plan performance rights 237,677	
Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	600,000 ordinary shares sold on market	

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

### Appendix 3Y Change of Director's Interest Notice

Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts	No
detailed above traded during a +closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to	
allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.